157 related articles for article (PubMed ID: 38720568)
21. Considerations for master protocols using external controls.
Chen J; Li XN; Lu CC; Yuan S; Yung G; Ye J; Tian H; Lin J
J Biopharm Stat; 2024 Feb; ():1-23. PubMed ID: 38363805
[TBL] [Abstract][Full Text] [Related]
22. Radiotherapy trial quality assurance processes: a systematic review.
Brooks C; Miles E; Hoskin PJ
Lancet Oncol; 2024 Mar; 25(3):e104-e113. PubMed ID: 38423056
[TBL] [Abstract][Full Text] [Related]
23. Mobilizing the clinical trial ecosystem to drive adoption of master protocols.
Bronson A; Chase MK; Fisher K; Millar D; Perlmutter J; Richardson N
Clin Trials; 2022 Dec; 19(6):690-696. PubMed ID: 36086812
[TBL] [Abstract][Full Text] [Related]
24. Novel Study Designs in Precision Medicine - Basket, Umbrella and Platform Trials.
Ravi R; Kesari HV
Curr Rev Clin Exp Pharmacol; 2022; 17(2):114-121. PubMed ID: 34455953
[TBL] [Abstract][Full Text] [Related]
25. Master protocols in clinical trials: a universal Swiss Army knife?
Sudhop T; Brun NC; Riedel C; Rosso A; Broich K; Senderovitz T
Lancet Oncol; 2019 Jun; 20(6):e336-e342. PubMed ID: 31162107
[TBL] [Abstract][Full Text] [Related]
26. Implementation of three dimensional conformal radiation therapy: prospects, opportunities, and challenges.
Vijayakumar S; Chen GT
Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):979-83. PubMed ID: 7493859
[TBL] [Abstract][Full Text] [Related]
27. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
[TBL] [Abstract][Full Text] [Related]
28. Radical multimodality therapy for malignant pleural mesothelioma.
Abdel-Rahman O; Elsayed Z; Mohamed H; Eltobgy M
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD012605. PubMed ID: 29309720
[TBL] [Abstract][Full Text] [Related]
29. A Road Map for Designing Phase I Clinical Trials of Radiotherapy-Novel Agent Combinations.
Brown SR; Hinsley S; Hall E; Hurt C; Baird RD; Forster M; Scarsbrook AF; Adams RA
Clin Cancer Res; 2022 Sep; 28(17):3639-3651. PubMed ID: 35552622
[TBL] [Abstract][Full Text] [Related]
30. Umbrella and basket trials in oncology: ethical challenges.
Strzebonska K; Waligora M
BMC Med Ethics; 2019 Aug; 20(1):58. PubMed ID: 31443704
[TBL] [Abstract][Full Text] [Related]
31. Development and evaluation of a de-escalation training intervention in adult acute and forensic units: the EDITION systematic review and feasibility trial.
Price O; Papastavrou Brooks C; Johnston I; McPherson P; Goodman H; Grundy A; Cree L; Motala Z; Robinson J; Doyle M; Stokes N; Armitage CJ; Barley E; Brooks H; Callaghan P; Carter LA; Davies LM; Drake RJ; Lovell K; Bee P
Health Technol Assess; 2024 Jan; 28(3):1-120. PubMed ID: 38343036
[TBL] [Abstract][Full Text] [Related]
32. Challenges to quality assurance of surgical interventions in clinical oncology trials: A systematic review.
Butterworth JW; Boshier PR; Mavroveli S; Van Lanschot JB; Sasako M; Reynolds JV; Hanna GB
Eur J Surg Oncol; 2021 Apr; 47(4):748-756. PubMed ID: 33059943
[TBL] [Abstract][Full Text] [Related]
33. Aiding the Adoption of Master Protocols by Optimizing Patient Engagement.
Huml RA; Collyar D; Antonijevic Z; Beckman RA; Quek RGW; Ye J
Ther Innov Regul Sci; 2023 Nov; 57(6):1136-1147. PubMed ID: 37615880
[TBL] [Abstract][Full Text] [Related]
34. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
Janiaud P; Serghiou S; Ioannidis JPA
Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
[TBL] [Abstract][Full Text] [Related]
35. Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.
Love SB; Cafferty F; Snowdon C; Carty K; Savage J; Pallmann P; McParland L; Brown L; Masters L; Schiavone F; Hague D; Townsend S; Amos C; South A; Sturgeon K; Langley R; Maughan T; James N; Hall E; Kernaghan S; Bliss J; Turner N; Tutt A; Yap C; Firth C; Kong A; Mehanna H; Watts C; Hills R; Thomas I; Copland M; Bell S; Sebag-Montefiore D; Jones R; Parmar MKB; Sydes MR
Trials; 2022 Sep; 23(1):757. PubMed ID: 36068599
[TBL] [Abstract][Full Text] [Related]
36. Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials.
Collignon O; Gartner C; Haidich AB; James Hemmings R; Hofner B; Pétavy F; Posch M; Rantell K; Roes K; Schiel A
Clin Pharmacol Ther; 2020 May; 107(5):1059-1067. PubMed ID: 32017052
[TBL] [Abstract][Full Text] [Related]
37. Quality assurance of research protocols conducted in the community: the National Institute on Drug Abuse Clinical Trials Network experience.
Rosa C; Campbell A; Kleppinger C; Sampson R; Tyson C; Mamay-Gentilin S
Clin Trials; 2009 Apr; 6(2):151-61. PubMed ID: 19342468
[TBL] [Abstract][Full Text] [Related]
38. Design and analysis of umbrella trials: Where do we stand?
Ouma LO; Wason JMS; Zheng H; Wilson N; Grayling M
Front Med (Lausanne); 2022; 9():1037439. PubMed ID: 36313987
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
